25I Stock Chart & Stats
€0.06
€0.00(0.00%)
At close: 4:00 PM EDT
€0.06
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.02 - €0.18
Previous CloseN/A
Volume0.00
Average Volume (3M)133.00
Market Cap
€25.50M
Enterprise Value€20.22
Total Cash (Recent Filing)€1.35M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta7.52
Next Earnings
May 25, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding623,911,400
10 Day Avg. Volume100
30 Day Avg. Volume133
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)44.28
Price to Sales (P/S)0.00
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal DebtEssentially zero debt limits near-term interest and refinancing pressure, preserving financial flexibility while the company advances its pharmaceutical assets. This gives management more room to pursue development or partnering options without servicing a large existing leverage burden.
Narrowing LossesThe narrower 2025 loss suggests the cost base may have reduced from earlier periods, improving the company’s ability to control spending. If maintained, this discipline could extend its development runway and reduce the scale of funding required to progress its pipeline.
Partnership-Based Monetization ModelA partnership-oriented model can let ImmuPharma pursue asset value without building a large integrated sales infrastructure. Licensing, milestones, royalties, and collaboration income provide several potential monetization routes if its drug candidates achieve meaningful clinical or commercial progress.
Bears Say
No Recent RevenueZero revenue across four years indicates that the company has not yet established recurring commercial income from its assets. This leaves financial performance dependent on future development success, partnering transactions, or external funding rather than an operating revenue base.
Persistent Cash BurnConsistently negative operating and free cash flow means the current business consumes cash rather than funding itself. Unless the operating model changes or a partnering transaction generates proceeds, continued development is likely to require further financing and disciplined cash management.
Fragile Equity PositionThe swing into negative equity demonstrates a fragile and volatile capital structure despite minimal debt. Recurring losses can continue to erode the equity base, potentially narrowing financing flexibility and increasing dependence on new capital to sustain research and development.
ImmuPharma News
25I FAQ
What was ImmuPharma PLC’s price range in the past 12 months?
ImmuPharma PLC lowest stock price was €0.02 and its highest was €0.18 in the past 12 months.
What is ImmuPharma PLC’s market cap?
ImmuPharma PLC’s market cap is €25.50M.
When is ImmuPharma PLC’s upcoming earnings report date?
ImmuPharma PLC’s upcoming earnings report date is May 25, 2027 which is in 251 days.
How were ImmuPharma PLC’s earnings last quarter?
ImmuPharma PLC released its earnings results on Sep 15, 2026. The company reported -€0.009 earnings per share for the quarter.
Is ImmuPharma PLC overvalued?
According to Wall Street analysts ImmuPharma PLC’s price is currently Overvalued.
Does ImmuPharma PLC pay dividends?
ImmuPharma PLC does not currently pay dividends.
What is ImmuPharma PLC’s EPS estimate?
ImmuPharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmuPharma PLC have?
ImmuPharma PLC has 623,911,400 shares outstanding.
What happened to ImmuPharma PLC’s price movement after its last earnings report?
ImmuPharma PLC reported an EPS of -€0.009 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ImmuPharma PLC?
Currently, no hedge funds are holding shares in DE:25I
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ImmuPharma PLC
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis. Its pre-clinical products include BioAMB, a peptide-based drug of Amphotericin-B formulations for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Technical Analysis
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―
SkinBioTherapeutics
―
Poolbeg Pharma Ltd.
―